Context: Endocannabinoids (ECs) have a role in obesity by affecting appetite and through peripheral effects. Obesity is associated with a dysregulation of the endocannabinoid system (ECS). Objective: We aimed to determine the ECS in subcutaneous adipose tissue (AT) in obese subject and investigate the influence of diet-induced weight loss on this system. Design: The obese study participants underwent a 12 weeks diet regimen resulting in 10-12% weight loss. All study participants underwent fasting blood samples and AT biopsies from abdomen and gluteal region, the obese subjects both before and after weight loss. Setting and participants: A total of 21 healthy obese individuals (10 men/11 women, age 39.5 ± 1.6 years, body mass index (BMI): 37.5±0.8 kg m À2 ) and 21 age-and gender-matched lean subjects (BMI: 23.8±0.4 kg m À2 ) were studied. Main outcome measures: The activity of ECS in AT was determined by measuring arachidonoyl glycerol (2-AG) and N-arachidonoylethanolamine/anandamide in AT by mass spectrometry and gene expressions of enzymes and receptors involved in the ECS. Results: The EC, 2-AG was reduced in obese individuals in the gluteal AT depot (Po0.01). Moreover, 2-AG increased in both depots in the obese subjects following weight loss (Po0.05). The gene expression of the CB1 was either not affected by the obese state (in the gluteal AT depot) or reduced (in the abdominal depot, Po0.05) and significantly affected by weight loss. The expression of the degrading enzymes FAAH, FAAH2, MGL and MGL2 was differently affected by obesity, AT depot and weight loss. Conclusion: We found reduced levels of 2-AG in subcutaneous AT in obesity, which increased after weight loss. In abdominal AT, the low CB1 expression was normalised after weight loss, whereas in gluteal AT the CB1 expression was reduced after weight loss. These findings support the concept of a dysregulated ECS in AT in association with obesity.
Introduction
Obesity is associated with a general over-activity of the endocannabinoid system (ECS) when measuring levels of arachidonoyl glycerol (2-AG) and N-arachidonoylethanolamine/anandamide (AEA) in plasma. [1] [2] [3] [4] As endocannabinoids (ECs) are produced on demand in specific tissues, 5 what is measured in the circulation is probably spillover of unknown origin. Previous studies indicate a dysregulation of the ECS in human obesity with differentially regulated levels in various AT depots. [6] [7] [8] Therefore, it will be of considerable interest to study the activity of the ECS in the adipose tissue (AT) to understand the importance of this system in lean and obese subjects.
The ECS consists of the cannabinoid receptors, the endogenous ligands for these receptors (the ECs) and the enzymes that produce and degrade these ligands. At least two cannabinoid receptors have been characterised 9 cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), but other receptors may be involved as well. 10 The CB1 is extensively distributed in the central nervous system, but it is also present in many tissues with relations to energy metabolism. 11 The CB2 is most common in the immune cells, 12 but it is also present in several other tissues including AT. 13 The two most widely studied ECs are 2-AG and AEA, which belongs to different groups of lipids termed as monoacylglycerols and N-acylethanolamines, respectively. 14 The ECs function mainly as neurotransmitters, and because of their highly lipophilic nature, they cannot be stored in vesicles and have to be produced on demand. 5 2-AG is synthesised by diacylglycerol lipase and degraded by monoglyceride lipase (MGL), 15 whereas AEA can be produced by N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and degraded by fatty acid amide hydrolase (FAAH). 16 Several forms of this enzyme exist, both FAAH2 and N-acylethanolamine-hydrolysing acid amidase but their roles are less characterised. 14 2-AG can also be degraded by FAAH, 17, 18 and genetic variations in the gene that encodes FAAH has been associated with overweight and obesity. 4 The ECS has been found to be a considerable participant in the control of energy balance and metabolism through both central and peripheral mechanisms. 19 Activation of the cannabinoid receptors is followed by increased food intake and body weight. 20, 21 Blockage of the ECS leads to decreased body weight and improved metabolic profile. 22 The peripheral effects of the ECS have been studied less than the central effects of the system. 19 Roche et al. 13 have established that the CB1 receptor is expressed in both pre-adipocytes and mature adipocytes and in visceral AT (VAT) as well as in subcutaneous AT (SAT), and we have previously shown a lower level of CB1 expression in VAT compared with SAT in lean subjects and similar levels in the two AT depots in obese individuals. 23 CB1 antagonism leads to increased lipolysis in white AT, 24 whereas CB1 stimulation increases glucose uptake in adipocytes. 25 As mentioned, there is a hypothesis that obesity is characterised by a dysregulation of the ECS. AT per se may be involved in the health complications of obesity, hence, it is of interest to characterise the ECS in human AT and its activity in AT in obesity. To advance our perspective of the implications of the ECS in human AT, we investigated SAT from two depots in lean control subjects and obese subjects before and after diet-induced weight loss. The levels of 2-AG and AEA in AT was determined by liquid chromatography mass spectrometry (LC-MS). Furthermore, the gene expression of CB1 and the synthesising and degrading enzymes of the system were investigated, and the possible impact of gender on this system in AT was determined.
Materials and methods

Study participants
The body mass index (BMI) of obese group was above 35 kg m À2 and age between 20 and 50 years. Exclusion criteria were diabetes (fasting plasma glucose above 7 mmol l
À1
), malignant disease, pregnancy or medication known to affect AT metabolism within the previous 3 months.
The lean group was matched to the obese group according to gender and age. BMI of the lean group should be between 22 and 27 kg m
À2
. All study participants signed written informed consent before investigations.
Study design
The obese group underwent clinical investigations at baseline and after 10 weeks (8 weeks weight loss by diet followed by 2 weeks weight stabilising period with the study participants' normal diet adjusted to the new weight). The weight loss of 10-12% was achieved by intake of a liquid very low calorie diet with 600 calories per day containing protein 41 g, carbohydrate 29 g and fat 5.6 g per 100 g, (NUPO nutritional powder, Flex pack Industry A/S, Greve, Denmark) plus 200 g of fruit and vegetables daily, and weekly motivating sessions with a dietician. The lean participants were investigated only once. The evening before clinical investigations (blood samples on one day, liposuctions on another) they all had the same meal (calorically adjusted for gender) and they fasted over night. They were also asked not to engage in excessive physical exercise or alcohol intake the day before and the morning of the clinical investigations.
The study was approved by the Central Denmark Region Committees on Biomedical Research Ethics and the Danish Data Protection Agency.
Investigations
Anthropometrics (BMI, waist-and hip-circumference) and bioimpedance to measure the fat mass were determined. AT samples were obtained by liposuction as previously described 26 from abdomen, subcutaneously (subcutaneous abdominal adipose tissue, SAAT) just below the level of the umbilicus in the midline, and from the gluteal region (subcutaneous gluteal adipose tissue, SGAT), between the greater trochanter and tuberositas ischii. This was performed under local anaesthesia with Lidocain 10 mg ml À1 without adrenalin. Fasting blood samples were drawn from all study participants and were analysed according to standard procedure at Department of Clinical Biochemistry at Aarhus University Hospital (glucose and lipids) except serum insulin, which were measured by ELISA (DAKO K6219, Electra Box Diagnostics Aps, Rødovre, Denmark) according to manufacturer's manual. The kit had a lower detection limit of 32.6 pmol l À1 and the absorbance was measured with a spectra reader photometer. The homoeostasis model assessment was used Measurements of 2-AG and AEA by LC-MS AEA and 2-AG were extracted from the AT tissue (0.1-0.6 g) and analysed using the procedure described previously by Artmann et al. 29 In short, the tissues were weighed and ethyl acetate/hexane (9:1) mixture was added to give a final volume of 40 ml per g of tissue. All samples were added to 500 pmol deuterium-labelled internal standards ( Real-time reverse transcription PCR for mRNA analysis AT samples (200 mg) were homogenised in TriZol reagent (Gibco BRL, Life Technologies, Roskilde, Denmark) and total RNA was extracted following the manufacturer's protocol. RNA was quantitated by measuring absorbency at 260 and 280 nm and the ratio was 1.8 or higher. The integrity of the RNA was checked by visual inspection of the two ribosomal RNAs on an ethidium bromide stained agarose gel. Reverse transcription was performed using random hexamer primers at 42 1C for 30 min and 92 1C for 2 min followed by 4 1C as described by the manufacturer (verso cDNA Kit from ABgene, Surrey, UK). Then, PCR-mastermix containing the specific primers and Taq DNA polymerase (KAPA SYBR FAST qPCR Kit, Kapabiosystems, Boston, MA, USA) were added.
The following primers were designed using the primer analysis software Oligo version 6.64 (Molecular Biology Insights, Inc., Cascade, CO, USA). ) . The housekeeping gene was tested for stability in the present intervention. The target and housekeeping gene were amplified in separate tubes. The increase in fluorescence was measured in real-time during the extension step. The threshold cycle (Ct) was calculated, and the relative gene expression was calculated essentially as described in the User Bulletin #2, 1997 from Perkin Elmer (Perkin Elmer Cetus, Norwalk, CT, USA). Briefly, the target gene (X0) to b2micro-globulin (R0) ratio in each sample before amplification was calculated as X0/R0 ¼ k Â 1/((2**DCt)), DCt is the difference between Ct-target and Ct-reference, and k is a constant, set to 1. All samples were amplified in duplicate.
Statistical analysis
Data are expressed as mean ± s.e.m. The three groups were compared by one-way repeated-measurements analysis of variance unless otherwise stated. If results were significant we performed post hoc test by Fishers least significant difference method between groups, with focus on lean versus obese at baseline or obese at baseline versus obese after weight loss. If variables were not normally distributed, comparisons were analysed by Kruskal-Wallis rank sum test. Relationships between EC and various enzymes were assessed by Pearson's correlation. Po0.05 is considered statistically significant. We used the statistical package Sigmaplot 11.0 with incorporated sigmastat (Systat software, Inc., Richmond, CA, USA) for performing statistical analysis
Results
Anthropometric and metabolic measures
Four subjects from the obese group left the study on their own request (three men and one woman). In total, we have tissue samples from 11 obese women before and 10 after the intervention, whereas 10 male subjects were investigated before and 7 after.
As expected from the matched design there were no differences between lean and obese subjects according to age or sex distribution, but a significant difference in BMI and fat mass (Table 1 ). In the obese group, the weight loss amounted to 14.8 ± 5.9 kg for men and 10.1 ± 0.9 kg for women, that is B12 and 10% of initial body weight, respectively, and correspond to about 21% reduction of the fat mass. All study participants lost weight (min: 6 kg per 7% of baseline weight, max: 19.8 kg per 17% of baseline weight). As shown in Table 1 the expected differences in glucose, insulin and lipids were observed between the lean and obese groups. After weight loss in the obese group lower levels of insulin (Po0.01), homoeostasis model assessment (Po0.05) and total cholesterol (Po0.05) were found.
Levels of 2-AG and AEA in AT These ECs were determined by LC-MS in AT taken from both the abdominal and gluteal fat depot. As compared with lean subjects the amount of 2-AG in obese individuals was
The endocannabinoid system in adipose tissue MF Bennetzen et al significantly lower in the gluteal depot (35% lower, Po0.05) and also a tendency to lower levels in the abdominal fat depot were found (reduced by 19%, P ¼ 0.09; Figure 1 ). After diet-induced weight loss in the obese subjects the level of 2-AG significantly increased in both AT depots (Po0.05, Figure 1 ). The level of AEA was neither affected by the obese state nor by weight loss (Figure 1) . No influence of gender on 2-AG or AEA in AT was found (data not shown).
Gene expression of enzymes and CB1 in AT levels Synthesising and degrading enzymes. Similar gene expression levels of FAAH and FAAH2 (degrading enzymes of both EC's) were found between lean and obese at baseline except from an increase in FAAH2 in SAAT of obese at baseline compared with lean (P ¼ 0.003, Figure 2 ). In SGAT, both FAAH and FAAH2 were decreased after weight loss (Po0.001 and Po0.05, respectively).
Also the expression of MGL and MGL2 (degrading enzymes of 2-AG) were reduced after weight loss in the SGAT depot. Lower levels of MGL were observed in obese compared with lean subjects in the SAAT depot. MGL2 was similarly expressed in SAAT between all three groups ( Figure 2) .
Concerning NAPE-PLD (synthesising enzyme for AEA), we found higher gene expression in SAAT of obese at baseline compared with lean (P ¼ 0.004), but no change after weight loss and similar levels in all three groups in SGAT (data not shown).
CB1
CB1 was highly expressed in lean compared with obese subjects in SAAT (Po0.01) and weight loss was followed by an increase in CB1 expression in obese subjects (Po0.001, Figure 3 ). CB1 expression in SAAT and SGAT does not behave similarly, as CB1 was expressed to the same degree in SGAT in lean and obese subjects and was reduced in SGAT after weight loss only in the obese group (Po0.01).
Comparing the abdominal and gluteal AT depots, we found similar CB1 levels in lean subjects, but higher levels in the gluteal compared with the abdominal depot in obese subjects at baseline (P ¼ 0.002, paired t-test). Concerning the impact of gender, the expression of CB1 was found to be higher in both AT depots in obese men compared with obese women (SAAT Po0.05, SGAT Po0.05, data not shown), with no gender differences among the lean subjects. The endocannabinoid system in adipose tissue MF Bennetzen et al
Correlations
There was a positive correlation between expression of CB1 and 2-AG levels in the SAAT depot (correlation coefficient 0.4, Po0.001), but no association in the gluteal depot or to AEA levels. Neither 2-AG nor AEA in AT were at baseline correlated to fat mass or any of the other anthropometric measurements (data not shown). Although weight loss enhanced 2-AG in both SAAT and SGAT there was no correlation between the weight loss or change in fat mass and the increment of 2-AG in the two depots. 2-AG was not correlated with the changes in metabolic factors associated with the weight loss (data not shown).
A negative correlation existed between 2-AG and FAAH2 levels (correlation coefficient -0.3, Po0.05), but not between 2-AG and MGL or MGL2 expression.
Discussion
In the present study, we demonstrated the presence of a complete ECS (ligands, receptors and biosynthetic/degradation enzymes) in human AT, which is in agreement with recent findings. 1, 30 Moreover, it was demonstrated that this ECS in AT was influenced by the obese state, by weight loss, and that SAT (abdominal versus gluteal) does not behave similar to weight loss. Several research groups find increased circulating EC levels with obesity. [1] [2] [3] These groups also find 2-AG to be the EC changing (the most) with weight changes. However, because the ECs are produced on demand and tightly regulated, it is unknown whether circulating levels provide useful information on ECS status in relevant tissues. We aimed to investigate ECS status in human SAT in the obese state, and our findings are compatible with the suggestion of a dysregulated ECS in the AT. This conclusion is built on our findings of lower levels of 2-AG in AT in the obese The endocannabinoid system in adipose tissue MF Bennetzen et al individuals, low levels that increase/normalise in association with weight loss, and low levels of CB1 expression in SAAT in the obese group, which also increases after weight loss. The finding of low levels of ECs in SAT from obese subjects is well in line with studies in obese rodents, 31, 32 demonstrating a pronounced reduction in subcutaneous EC in obese rodents, whereas the change in ECs in VAT was more modest after diet-induced obesity. Animal studies do indicate hyperactivity of the ECS in obesity in the intra-abdominal (epididymal) AT depot. 30, 33 Also human studies support the idea that the over-activation of the ECS is in the VAT. [6] [7] [8] Recent investigations of the ECs in SAT by Annuzzi el al.
34
in a small sample of obese and lean individuals did not detect significant difference between lean and obese subjects, whereas obese with type 2 diabetes had significant higher AEA and lower 2-AG levels. Concerning the lean and obese individuals their findings were in good agreement with our findings in a large sample size. Thus, the increased level of 2-AG in plasma in obesity is not caused by increased spillover from the SAT. However, it could be caused by increased activity in the intra-abdominal depot, and several studies have described an association between amount of VAT and plasma 2-AG levels. 2, 3 This is supported by Matias et al., 30 who performed peripheral measurements of EC in VAT. They revealed higher 2-AG levels in the VAT from obese subjects compared with lean, whereas they found higher levels of both 2-AG and AEA in serum from overweight subjects with diabetes, compared with healthy subjects. Di Marzo 7 was the first to suggest that an upregulation of the ECS in VAT and a downregulation of the system in SAT in obesity and diabetes might lead to excessive accumulation of VAT at the expense of SAT possibly resulting in development of diabetes and atherosclerosis. Previous studies with 5% weight loss did not show any difference in circulating EC levels, AT CB1 or AT FAAH mRNA gene levels. 1, 35 A study by Di Marzo et al. 36 investigated EC levels in viscerally obese men, who underwent 1 year lifestyle modifications. The intervention resulted in a weight loss of almost 7% of initial body weight, and following this life style intervention, circulating levels of 2-AG and AEA were significantly reduced (À62.3 and À7%, respectively), which was associated with the decrease in VAT and not to change in SAT, which is in accordance with our results. The reduced expression of CB1 in obese subjects, at least in the SAAT depot, is in accordance with our recent study, in which the amount of CB1 was determined by both mRNA and at the protein level (western blot) and this level was also found to be reduced in obese as compared with lean subjects. 23 We found a reduction in the degrading enzymes for both 2-AG (MGL, MGL2, FAAH and FAAH2) and AEA (FAAH and FAAH2) in SGAT with weight loss, but interestingly only an association between 2-AG and FAAH2. The reduction in enzyme levels could explain the increase in 2-AG levels in SGAT following weight loss, but the actions on the enzymes may not be as simple as previously anticipated. 37 Pagano et al. 25 investigated the differential levels of CB1 expression in both SAAT and SGAT. They found lower CB1 expression in SGAT of obese compared with lean individuals and higher CB1 expression in SAAT of obese compared with lean. Our results confirm these and other previous findings of increased CB1 expression in the SAAT of lean compared with obese subjects.
1,2,6
Pagano et al. 25 also investigated synthesising and degrading enzymes and found downregulation of FAAH in SGAT and, similar to us, upregulation of FAAH in SAAT of obese compared with lean and higher NAPE-PLD-levels in SGAT of obese in both AT compartments. The previously mentioned study by Engeli et al. also showed a reduction in CB1 and FAAH expression in SAAT with obesity, and they found a negative correlation between circulating EC's and FAAH expression in AT. 38 Some limitations in the present study should be mentioned. First, the ECS was investigated in two SAT depots and not in the potential metabolically more important VAT depot. On the other hand, CBR1 in VAT in human studies also seems to be reduced in obesity 2 and in our recent study 23 we found reduced CB1 protein in VAT as compared with SAT but ECs were not measured in that study. Moreover, whole AT was investigated containing several other cell types than adipocytes and accordingly we do not known the cell types of most importance for ECS in AT.
Overall it appears, that the ECS is dysregulated in association with obesity, with increased formation of ECs in the visceral depot and unaltered or increased CB1 receptor expression in the same depot, whereas in the subcutaneous abdominal adipose tissue (SAAT) from obese subjects, the production of 2-AG is reduced, as is CB1.
We investigated two different SAT depots, and were able to confirm our previous results of higher CB1 expression in gluteal AT compared with abdominal AT in obese subjects. 23 In addition, we found a different response to weight loss in the two depots; in gluteal adipose tissue FAAH and FAAH2 was reduced after weight loss, whereas in abdominal adipose tissue the expression of these enzymes were increased. Also for CB1 expression, the response to weight loss was opposite in the two depots; in abdominal adipose tissue CB1 expression increased after weight loss, whereas it decreased in gluteal adipose tissue after weight loss.
In conclusion, the amount of 2-AG was reduced in SAT from obese subjects and 2-AG increased/normalised after weight loss. Moreover, the expression of CB1 was reduced in SAAT in obese individuals. Thus, both one of the important endogenous ligands, 2-AG, and the main EC receptor were downregulated in the obese state, indicating the EC tone in SAAT is reduced in obesity, but can be increased (normalised) by a weight loss. In addition, weight loss caused opposite regulation of the ECS in SAAT compared with SGAT, which might be important for the AT metabolism in the two depots.
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